Download PDF
Endoscopy 2000; 32(10): 779-782
DOI: 10.1055/s-2000-7708
Original Article
© Georg Thieme Verlag Stuttgart · New York

Prospective Risk Assessment of Endoscopic Retrograde Cholangiography in Patients with Primary Sclerosing Cholangitis

S. J. van den Hazel 1 , F. H. J. Wolfhagen 2 , H. R. van Buuren 2 , P. C. van de Meeberg 3 , D. J. van Leeuwen, representing the Dutch PSC study group4
  • 1 Division of Gastroenterology and Hepatology, Academic Medical Center of the University of Amsterdam, The Netherlands
  • 2 Department of Internal Medicine, Albert Schweitzer Hospital, Zwijndrecht, The Netherlands
  • 3 Division of Gastroenterology and Hepatology, University Medical Center, Utrecht, The Netherlands
  • 4 Division of Gastroenterology and Hepatology, University of Alabama Health Center, Birmingham, Alabama, USA
Further Information

Publication History

Publication Date:
31 December 2000 (online)

Also available at
    Permissions and Reprints

Background and Study Aims: Direct endoscopic retrograde cholangiopancreatography (ERCP) has become the standard for establishing the diagnosis of primary sclerosing cholangitis (PSC), while endoscopic procedures play an increasingly important therapeutic role. However, many believe that this procedure carries a significant risk of infection and other complications. We assessed the incidence of complications within 1 week of ERCP in patients with PSC.

Patients and Methods: In a multicenter study, patients who underwent ERCP for (suspected) PSC were prospectively followed for the occurrence of complications after the procedure.

Results: A total of 106 ERCPs performed in 83 patients were evaluated. Complications occurred on ten occasions (9 %): pancreatitis (n = 3), cholangitis (n = 2), increase of cholestasis (n = 2), postsphincterotomy bleeding (n = 1), cystic duct perforation (n = 1), and venous thrombosis (n = 1). All complications resolved quickly with proper therapy. Complications were more likely when ERCP was done to evaluate specific complaints such as jaundice or recurrent cholangitis (9/59) than after a purely diagnostic ERCP (1/47 relative risk [RR] 7.2, 95 % confidence interval [CI] 1.00 to 153). Therapeutic interventions performed during ERCP (e. g. placement of endoprosthesis, dilation of strictures) also increased the risk of postprocedural complications (RR 4.5, 95 % CI 0.94 to 30).

Conclusions: ERCP is a safe method for establishing the diagnosis of PSC in asymptomatic patients (2 % complication rate). Although ERCP in symptomatic patients carries a higher risk (14 %), this can be justified by the benefits of endoscopic therapy.

References

  • 1 Johnson G K, Geenen J E, Venu R P, et al. Endoscopic treatment of biliary tract strictures in sclerosing cholangitis: a larger series and recommendations for treatment.  Gastrointest Endosc. 1991;  37 38-43
    PubMedGoogle Scholar
  • 2 Lillemoe K D, Pitt H A, Cameron J L. Primary sclerosing cholangitis.  Surg Clin N Am. 1990;  70 1381-1402
    PubMedGoogle Scholar
  • 3 Majoie C BLM, Reeders J WAJ, Sanders J B, et al. Primary sclerosing cholangitis: a modified classification of cholangiographic findings.  Am J Radiol. 1991;  157 495-497
    PubMedGoogle Scholar
  • 4 Cotton P B, Nickl N. Endoscopic and radiologic approaches to therapy in primary sclerosing cholangitis.  Semin Liver Dis. 1991;  11 40-48
    PubMedGoogle Scholar
  • 5 Beuers U, Spengler U, Sackmann M, et al. Deterioration of cholestasis after endoscopic retrograde cholangiography in advanced primary sclerosing cholangitis.  J Hepatol. 1992;  15 140-143
    CrossrefPubMedGoogle Scholar
  • 6 Kaplan M M. Medical approaches to primary sclerosing cholangitis.  Semin Liver Dis. 1991;  11 56-63
    PubMedGoogle Scholar
  • 7 Knox T A, Kaplan M M. A double blind controlled trial of oral pulse methotrexate therapy in the treament of primary sclerosing cholangitis.  Gastroenterology. 1994;  106 494-499
    CrossrefPubMedGoogle Scholar
  • 8 Lindor K D, Jorgensen R A, Anderson M L, et al. Ursodeoxycholic acid and methotrexate for primary sclerosing cholangitis: a pilot study.  Am J Gastroenterol. 1996;  91 511-515
    PubMedGoogle Scholar
  • 9 Beuers U, Spengler U, Kruis W, et al. Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial.  Hepatology. 1992;  16 707-714
    CrossrefPubMedGoogle Scholar
  • 10 Lindor K D. Ursodiol for primary sclerosing cholangitis. Mayo primary sclerosing cholangitis - ursodeoxycholic acid study group.  N Engl J Med. 1997;  336 691-695
    CrossrefPubMedGoogle Scholar
  • 11 Lombard M, Farrant M, Karani J, et al. Improving biliary-enteric drainage in primary sclerosing cholangitis: experience with endoscopic methods.  Gut. 1991;  32 1364-1368
    PubMedGoogle Scholar
  • 12 Lee J G, Schutz S M, England R E, et al. Endoscopic therapy of sclerosing cholangitis.  Hepatology. 1995;  21 661-667
    CrossrefPubMedGoogle Scholar
  • 13 Gaing A A, Geders J M, Cohen S A, Siegel J H. Endoscopic management of primary sclerosing cholangitis: review and report of an open series.  Am J Gastroenterol. 1993;  88 2000-2008
    PubMedGoogle Scholar
  • 14 van Milligen de Wit A W, van Bracht J, Rauws E A, et al. Endoscopic stent therapy for dominant extrahepatic bile duct strictures in primary sclerosing cholangitis.  Gastrointest Endosc. 1996;  44 293-299
    CrossrefPubMedGoogle Scholar
  • 15 Ostroff J W, Shapiro H A. Endoscopic management of dominant biliary strictures associated with sclerosing cholangitis.  Gastrointest Endosc. 1993;  39 328
    PubMedGoogle Scholar
  • 16 Silverman W B, Davidson W I, Kaw M , et al. Complication rate (CR) of endoscopic retrograde cholangio-pancreatography (ERCP) in patients with primary sclerosing cholangitis (PSC): is it safe?.  Gastroenterology. 1994;  106 A359
    PubMedGoogle Scholar

S. J. van den Hazel,M.D. 

Dept. of Internal Medicine Academic Hospital Nijmegen

PO Box 9101, 6500 HB Nijmegen The Netherlands

Fax: Fax:+ 31-20-883-7412

Email: E-mail:vandenhazel@hetnet.nl